Correspondence 0001628280-26-027634 from Veradermics, Inc (MANE) (CIK 0001827635)
Veradermics, Inc (MANE) (CIK 0001827635)
Date: April 27, 2026 · CIK: 0001827635 · Accession: 0001628280-26-027634
AI Filing Summary & Sentiment
File numbers found in text: 333-295356
Letter
Document
April 27, 2026
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Lauren Hamill
Re: Veradermics, Incorporated
Registration Statement on Form S-1
File No. 333-295356
Acceleration Request
Requested Date: April 29, 2026
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Veradermics, Incorporated (the “Company”) for acceleration of the effective time of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on April 29, 2026, or at such later time as the Company or its outside counsel, Ropes & Gray LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
Very truly yours,
JEFFERIES LLC
Show Raw Text
CORRESP 1 filename1.htm Document April 27, 2026 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: Veradermics, Incorporated Registration Statement on Form S-1 File No. 333-295356 Acceleration Request Requested Date: April 29, 2026 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Veradermics, Incorporated (the “Company”) for acceleration of the effective time of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on April 29, 2026, or at such later time as the Company or its outside counsel, Ropes & Gray LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Signature Page Follows] Very truly yours, JEFFERIES LLC LEERINK PARTNERS LLC CITIGROUP GLOBAL MARKETS INC. CANTOR FITZGERALD & CO. As representatives of the underwriters JEFFERIES LLC By: /s/ Jack Fabbri Name: Jack Fabbri Title: Managing Director LEERINK PARTNERS LLC By: /s/ Dan Dubin, M.D. Name: Dan Dubin, M.D. Title: Vice Chairman, Head of Biopharma Investing Banking CITIGROUP GLOBAL MARKETS INC. By: /s/ John Whittaker Name: John Whittaker Title: Managing Director, Co-Head of NAM Biotech CANTOR FITZGERALD & CO. By: /s/ Jason Fenton Name: Jason Fenton Title: Managing Director, Co-Head Equity Capital Markets [Signature Page to Underwriters’ Acceleration Request]